Trial · NCT07913568
A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy（NCCH2407/MK014）
NCT07913568, Phase 2, Not yet recruiting, National Cancer Center, Japan
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy（NCCH2407/MK014）. Trials, record NCT07913568. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913568
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy（NCCH2407/MK014）
- NCT number
- NCT07913568
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 32 participants, estimated
- Lead sponsor
- National Cancer Center, Japan
- Conditions
- Ovarian Clear Cell Carcinoma
- Interventions
- Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
- First posted
- 2026-11-03
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) assessed by the central review | Baseline up to 3 years. Overall Response is assessed every 8 weeks until 24 weeks after initiation of protocol treatment, and every 12 weeks after 25 weeks and after termination. It continues until PD confirmation or post-study treatment initiation. | |
| Secondary | Objective Response Rate (ORR) as assessed by the investigator (site assessment) | Baseline up to 3 years. Overall Response is assessed every 8 weeks until 24 weeks after initiation of protocol treatment, and every 12 weeks after 25 weeks and after termination. It continues until PD confirmation or post-study treatment initiation. | |
| Secondary | Progression-Free Survival (PFS) | From baseline up to 3 years | |
| Secondary | Overall Survival (OS) | From baseline up to 3 years | |
| Secondary | Disease Control Rate (DCR) | From baseline up to 3 years | |
| Secondary | Incidence of adverse events | From baseline up to 3 years | |
| Secondary | Incidence of Adverse Reactions | From baseline up to 3 years | |
| Secondary | Incidence of Serious Adverse Events/ Adverse Reactions | From baseline up to 3 years | |
| Secondary | Duration of Response (DoR) | From baseline up to 3 years | |
| Secondary | Time to Response (TTR) | From baseline up to 3 years |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913568
GET https://conductscience.org/api/trials/v1/NCT07913568/registered